Newsroom

Mallinckrodt Opens New Global Centre for Medical Device R&D

• Mallinckrodt consolidates global medical device R&D activities to new centre in Blanchardstown creating 45 new roles in device engineering

Dublin, Monday, 15 May 2017 – Mallinckrodt plc (NYSE: MNK), a leading specialty pharmaceutical company, today officially opened its new global medical device engineering centre at its campus at the College Business and Technology Park in Blanchardstown, Dublin 15. Mallinckrodt is consolidating global device research and development (R&D) activities to this new centre, creating 45 highly skilled jobs in a range of disciplines including product design, core electronics, electro-mechanical engineering and software development.

The opening of this new R&D facility brings Mallinckrodt’s total investment at its Cruiserath Road location to €95 million and the creation of 120 new roles in a variety of areas including manufacturing, supply chain management and other support functions. This project is supported by the Department of Jobs, Enterprise and Innovation through IDA Ireland.

Mallinckrodt has a long history and presence in Ireland for nearly 25 years. It’s new Global Device Engineering centre will be officially opened this morning by Minister for Social Protection, Leo Varadkar TD, Mallinckrodt President and Chief Executive Officer, Mark Trudeau and Deputy Mayor of Fingal County Council, Councillor Eithne Loftus.

Mallinckrodt’s new location on the Cruiserath Road in Blanchardstown also houses its corporate offices in Ireland and a state-of-the-art manufacturing facility which is currently undergoing commissioning and validation.

Commenting, Leo Varadkar, local TD and Minister for Social Protection, said "I am very pleased to mark the opening of Mallinckrodt’s Global Device Engineering facility at its new location in Blanchardstown. It’s great to see a medical device R&D facility like this investing in west Dublin.  Mallinckrodt is creating jobs, and enhancing Ireland’s reputation as an important centre for R&D, which is a key plank in the Government’s economic development strategy. Ultimately, the devices developed here in this facility will make a real difference to the lives of patients both in Ireland and internationally.”

Commenting, Mark Trudeau, President and Chief Executive Officer of Mallinckrodt, said: “Mallinckrodt has had a significant manufacturing and business presence in Ireland for almost a quarter of a century. In that time, our employees here have been, and continue to be, a tremendous asset to our global operations. This new Global Device Engineering facility allows us to centralize our device R&D skills and expertise in developing the next generation of products for a number of important and rare conditions to make a significant difference to the lives of patients.”

Commenting, Deputy Mayor of Fingal County Council, Councillor Eithne Loftus, said: “I welcome the partnership between Mallinckrodt and Fingal County Council in helping to bring the facilities at its new location in the College Business and Technology Park to completion in less than two years. Fingal is seeing considerable investment in R&D and technology from a variety of Irish and international companies. The Council is committed to supporting investments with responsive services and co-operation in the interests of job creation and the economic development of Fingal.”

Welcoming today’s announcement, Dr. David Keenan, Vice President, Global External Supply and Managing Director, Mallinckrodt Pharmaceuticals, Ireland, said, “The opening of this Global Device Engineering facility marks the completion of the main construction activities at our new location in the College Business and Technology Park, Blanchardstown. This has taken less than two years and has included the construction of corporate offices, a new state-of-the-art manufacturing facility and this new Global Device Engineering centre. This has been an exceptional achievement by our internal project teams and contractors, with the support of the IDA and Fingal County Council.”

Coolmine Therapeutic Community
This morning, Mallinckrodt has also announced a new corporate partnership with Coolmine Therapeutic Community, providing financial and other supports to assist in providing drug and alcohol treatment services to the community. Coolmine provides day and residential services to men and women with problematic substance use and their families in Ireland. Mallinckrodt is granting initial financial support of €15,000 to Coolmine. Commenting, Dr. David Keenan said: “The Coolmine Therapeutic Community provides critical supports and services for families and individuals encountering very serious challenges in their lives. We are pleased to support them in their essential work.”
ENDS
Note to Editors:

• Mallinckrodt had existing manufacturing operations in Ireland at Damastown, Mulhuddart, D.15, which were sold in December 2015.

For reference, issued on behalf of Mallinckrodt Pharmaceuticals by FTI Consulting. For media queries, contact:

Jim Devlin, e. jim.devlin@fticonsulting.com; d. +353 (0)1 66 33 600; m. +353 (0)87 2631057

Or

Patrick Berkery, e. Patrick.berkery@fticonsulting.com; d. +353 (0)1 66 33 684;

m. +353 (0)86 6025988

ABOUT MALLINCKRODT
Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and hemostasis products. The company's core strengths include the acquisition and management of highly regulated raw materials and specialized chemistry, formulation and manufacturing capabilities. The company's Specialty Brands segment includes branded medicines, and its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing. To learn more about Mallinckrodt, visit www.mallinckrodt.com.

Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.